Nanoscope Therapeutics
↗Dallas, USA
Nanoscope Therapeutics is a late-stage clinical biotechnology company developing gene-agnostic optogenetic therapies to restore vision in patients with retinal degenerative diseases. Its proprietary Multi-Characteristic Opsin (MCO) platform uses ambient light-activated molecules to re-sensitize the retina, bypassing damaged photoreceptors and utilizing existing retinal circuitry to transmit visual signals to the brain.
The company's lead candidate, MCO-010, has demonstrated significant and durable vision restoration in randomized clinical trials for Retinitis Pigmentosa (RP) and Stargardt disease. Unlike traditional gene therapies that target specific mutations, Nanoscope's approach is disease-agnostic, potentially offering a universal treatment for millions of patients with severe vision loss regardless of their underlying genetic cause.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:Pre-revenue
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$13.9M
Investors:National Eye Institute (NIH), AG Collective Capital, CKG Management, U.S. Department of Health and Human Services
PIPELINE
Stage:Commercial
Lead Drug Stage:BLA Submission
Modalities:Gene therapy, Optogenetics, AAV vector
Active Trials:3
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Verana Health (Data collaboration for RP research), TechFW (Business incubator support)
COMPETITION
Position:Emerging
Competitors:Ocugen, GenSight Biologics, Bionic Sight, MeiraGTx, Atsena Therapeutics, Adverum Biotechnologies, EyePoint Pharmaceuticals
LEADERSHIP
Key Executives:
Sulagna Bhattacharya - Co-founder and CEO
Samarendra Mohanty, PhD - Co-founder, President and CSO
Samuel Barone, MD - Chief Medical Officer
Scientific Founders:Samarendra Mohanty, PhD, Sulagna Bhattacharya
Board Members:Alvaro Guillem (Chairman), Sunil Gupta, MD, Sulagna Bhattacharya
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Nanoscope Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.